Documento de Consenso 2006 de la Sociedad Española de Reumatología sobre la osteoporosis posmenopáusica

American Association of Clinical Endocrinologist medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteopoosis, 2001 edition, with selected updates for 2003. Endocr Pract. 2003; 9: 551-64. Beral, 2003, Breast cancer and hormone replacement therapy in the Million Women Study, Lancet, 362, 419, 10.1016/S0140-6736(03)14596-5 Bischoff-Ferrari, 2005, Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials, JAMA, 293, 2257, 10.1001/jama.293.18.2257 Black, 1996, Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures, Lancet, 348, 1535, 10.1016/S0140-6736(96)07088-2 Black, 2003, The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis, N Engl J Med, 349, 1207, 10.1056/NEJMoa031975 Boonen, 2005, Identifying postmenopausal women with osteoporosis by calcaneal ultrasound, metacarpal digital X-ray radiogrametry and phalangeal radiographic absorptiometry: a comparative study, Osteoporosis Int, 16, 93, 10.1007/s00198-004-1660-z Bone, 2004, Ten years’ experience with alendronate for osteoporosis in postmenopausal women, N Engl J Med, 350, 1189, 10.1056/NEJMoa030897 Cosman, 2001, Parathyroid hormone added to established hormone therapy: effects on vertebral fractures and maintenance of bone mass after parathyroid hormone withdrawal, J Bone Miner Res, 16, 925, 10.1359/jbmr.2001.16.5.925 Chapuy, 1992, Vitamin D3 and calcium to prevent hip fractures in elderly women, N Engl J Med, 327, 1637, 10.1056/NEJM199212033272305 Chesnut, 2000, A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteporosis: the Prevent Recurrence of Osteoporotic Fractures Study, AmJMed, 109, 267 Cranney, 2002, Meta-analyses of therapies for postmenopausal osteoporosis. IX. Summary of meta-analyses of therapies for postmenopausal osteoporosis, Endocr Rev, 23, 570, 10.1210/er.2001-9002 Diamond, 2003, Management of acute osteoporotic vertebral fractures: a nonrandomized trial comparing percutaneous vertebraplasty with conservative therapy, Am J Med, 114, 257, 10.1016/S0002-9343(02)01524-3 Eddy, 1998, Osteoporosis: Review of evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis, Osteoporos Int, 8, S1 Ettinger, 1999, Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene Results from a 3-year randomized clinical trial, JAMA, 282, 637, 10.1001/jama.282.7.637 Grady, 2002, Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and estrogen/progestin replacement study follow-up (HERS II), JAMA, 288, 49, 10.1001/jama.288.1.49 Greenspan, 2005, 1222 Garnero, 1999, A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover, Bone, 24, 603, 10.1016/S8756-3282(99)00087-3 2003, Osteoporosis postmenopáusica. Guía de Práctica Clínica, Rev Clin Esp, 203, 496, 10.1016/S0014-2565(03)71338-1 Harris, 1999, Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial Vertebral Efficacy with Risedronate Therapy (VERT) Study Group, JAMA., 282, 1344, 10.1001/jama.282.14.1344 Hulley, 2002, Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and estrogen/progestin replacement study follow-up (HERS II), JAMA., 288, 58, 10.1001/jama.288.1.58 Marin, 2006, Relationship betwen bone quantitative ultrasound an fractures a meta-analysis, J Bone Miner Res, 21, 1127, 10.1359/jbmr.060417 Martino, 2005, Safety assessment of raloxifene over eight years in a clinical trial setting, Curr Med Res Opin, 21, 1441, 10.1185/030079905X61839 Mellstrom, 2004, Seven years of treatment with risedronate in women with postmenopausal osteoporosis, Calcif Tissue Int, 75, 462, 10.1007/s00223-004-0286-7 Meunier, 2004, The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis, N Engl J Med, 350, 459, 10.1056/NEJMoa022436 Miller, 2005, Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study, J Bone Miner Res, 20, 1315, 10.1359/JBMR.050313 Neer, 2001, Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis, N Engl J Med, 344, 1434, 10.1056/NEJM200105103441904 1994, NIH Consensus development panel on optimal calcium intake, JAMA, 272, 1942, 10.1001/jama.1994.03520240070044 2001, JAMA, 285, 785, 10.1001/jama.285.6.785 2001, Documento de la Sociedad Española de Reumatología sobre la osteoporosis posmenopáusica, Rev Esp Reumatol, 28, 148 2003, Documento de Consenso sobre Osteoporosis Postmenopáusica de la Sociedad Española de Reumatología, Rev Esp Reumatol, 30, 565 Prodigy Guidance. Osteoporosis-treatment and prevention of fragility fracture, 2006. Disponible en: http://www.prodigy.nhs.uk/ Pyon, 2006, Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen, Clin Ther, 28, 475, 10.1016/j.clinthera.2006.04.006 Reginster, 2005, Strontium ralenate reduce the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study, J Clin Endocrinol Metab, 90, 2816, 10.1210/jc.2004-1774 2002, Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women’s Health Initiative randomized controlled trial, JAMA, 288, 321, 10.1001/jama.288.3.321 Tornero, 2006, Documento de Consenso de la Sociedad Española de Reumatología para el uso de opioides en el tratamiento del dolor reumático, Reumatol Clin, 2, 50, 10.1016/S1699-258X(06)73083-2 Watts, 1999, Clinical utility of biochemical markers of bone remodeling, Clin Chem, 45, 1359, 10.1093/clinchem/45.8.1359 Watts, 1990, Intermittent cyclical etidronate treatment of postmenopausal osteoporosis, N EnglJ Med, 323, 73, 10.1056/NEJM199007123230201 WHO Study Group on assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical Report Series 843. Geneva: WHO; 1994.